Last reviewed · How we verify

Progesterone 200 MG

Instituto Bernabeu · FDA-approved active Small molecule Quality 5/100

Progesterone 200 MG is a Small molecule drug developed by Instituto Bernabeu. It is currently FDA-approved. Also known as: Prometrium.

Progesterone 200 MG, marketed by Instituto Bernabeu, is a hormonal therapy currently available in the market. The key composition patent for this drug is set to expire in 2028, providing a clear period of exclusivity. The primary risk lies in the potential increase in competition following the patent expiry.

At a glance

Generic nameProgesterone 200 MG
Also known asPrometrium
SponsorInstituto Bernabeu
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Progesterone 200 MG

What is Progesterone 200 MG?

Progesterone 200 MG is a Small molecule drug developed by Instituto Bernabeu.

Who makes Progesterone 200 MG?

Progesterone 200 MG is developed and marketed by Instituto Bernabeu (see full Instituto Bernabeu pipeline at /company/instituto-bernabeu).

Is Progesterone 200 MG also known as anything else?

Progesterone 200 MG is also known as Prometrium.

What development phase is Progesterone 200 MG in?

Progesterone 200 MG is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing